What Analysts Are Saying About Paragon 28 Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Paragon 28 (NYSE:FNA), with recent ratings ranging from bullish to bearish. The average 12-month price target is $16.57, down from $17.00, with actions including lowering and maintaining ratings. Paragon 28, a medical devices company, shows a positive revenue trend with a 17.58% growth rate but faces challenges in profitability and asset utilization. Its financial performance indicates robust financial management despite a smaller market capitalization compared to industry peers.
May 09, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts' mixed ratings and a slight decrease in the average price target may create short-term volatility in Paragon 28's stock. The company's strong revenue growth contrasts with its profitability challenges, impacting investor sentiment.
The mixed analyst ratings and revised price targets reflect uncertainty and varied expectations for Paragon 28's future performance. While the positive revenue trend is encouraging, the profitability and asset utilization challenges may temper investor enthusiasm, leading to potential short-term volatility in the stock price. The overall impact is considered neutral due to these counterbalancing factors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100